Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech reports over 80% lesion reduction in a rare skin cancer trial, though phase, enrollment and durability data remain undisclosed in the announcement.
Topic
Krystal Biotech
Topic
Krystal Biotech
Krystal Biotech Reports KB113 Lesion Regression Data in Gorlin Syndrome
Krystal Biotech reports KB113, a topical gene therapy candidate, drove lesion regression in Gorlin syndrome patients — an early s…